Lunai Bioworks Inc. (RENB)
NASDAQ: RENB
· Real-Time Price · USD
1.42
0.00 (0.00%)
At close: Jun 09, 2025, 3:59 PM
1.54
8.45%
After-hours: Sep 30, 2025, 07:59 PM EDT
Company Description
Lunai Bioworks, Inc. is a pre-clinical stage biotechnology company, which engages in the development of genetically modified cellular and immune-therapy technologies used for the treatment of infectious diseases and cancer.
Its pipeline consists of ENOB-HV-01, ENOB- HV-11, ENOB-HV-12, ENOB-DB-01, ENOB-DC-01, ENOB-DC-11, and ENOB-DC-21.
The company was founded by Rene Sindlev and Serhat Gumrukcu on January 18, 2011 and is headquartered in Los Angeles, CA.
Lunai Bioworks Inc.
| Country | United States |
| IPO Date | Feb 7, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 25 |
| CEO | David H. Weinstein |
Contact Details
Address: 2080 Century Park East Los Angeles, California United States | |
| Website | https://renovarogroup.com |
Stock Details
| Ticker Symbol | RENB |
| Exchange | NASDAQ |
| Fiscal Year | July - June |
| Reporting Currency | USD |
| CIK Code | 0001527728 |
| CUSIP Number | 29350E104 |
| ISIN Number | US29350E1047 |
| Employer ID | 45-2259340 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| David H. Weinstein | Chief Executive Officer & Director |
| Nathen Fuentes CPA | Chief Financial Officer |
| Greg Duczynski Ph.D. | Senior Vice President for Clinical Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 29, 2025 | 10-K | Annual Report |
| Sep 26, 2025 | SCHEDULE 13G | Filing |
| Sep 24, 2025 | 8-K | Current Report |
| Sep 05, 2025 | 8-K | Current Report |
| Aug 26, 2025 | 8-K | Current Report |
| Aug 06, 2025 | 8-K | Current Report |
| Jul 30, 2025 | DEF 14A | Filing |
| Jul 25, 2025 | 8-K | Current Report |
| Jul 18, 2025 | PRE 14A | Filing |
| Jul 14, 2025 | 8-K | Current Report |